These products, which are based on well-known injectable drugs are designed to enhance patient safety, compliance and comfort. CROSSJECT develops a product portfolio that combines well-known drugs with an innovative mode of injection. It is particularly well suited to emergency situation and most chronic treatments, and can be adapted to a wide range of specific situations. CROSSJECT’s pre-filled and single-use ZENEO® injection systems are unique in that they can be tailored to deliver drugs intra-dermally, subcutaneously and intramuscularly. This means that the ZENEO® platform can allow a wide range of drugs and vaccines for a broad range on indications to be developed and approved in a very short period of time. ZENEO® is the result of € 60M of investments through 12 years of R&D and is protected by more than 400 patents. It already exists under its industrial form and was subject to 8 clinical studies including TNF mabs (for preclinical studies) and vaccines.
Chenôve, FR
Size (employees)
31 (est)
CROSSJECT was founded in 2001 and is headquartered in Chenôve, FR
Report incorrect company information

CROSSJECT Office Locations

CROSSJECT has an office in Chenôve
Chenôve, FR (HQ)
60 Avenue du 14 Juillet
Show all (1)
Report incorrect company information

CROSSJECT Financials and Metrics

CROSSJECT Financials

Market capitalization (31-Oct-2017)

36.5 m

Closing share price (31-Oct-2017)

CROSSJECT's current market capitalization is €36.5 m.
Show all financial metrics
Report incorrect company information